1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Prescient Therapeutics Ltd (PTX) - Financial and Strategic SWOT Analysis Review

Summary

Prescient Therapeutics Limited (Prescient Therapeutics) is a biopharmaceutical company. The company discovers and develops immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immunotherapeutic products based on its Co-X-Gene and fowlpox virus (FPV) delivery technologies. Prescient Therapeutics's products under clinical development include skin cancer immunotherapeutic, VIR201, VIR501, and therapeutic HBV vaccine. The company’s VIR201 vaccine is used a HIV vaccine; and VIR501 is a prostate cancer vaccine. Its TG4001 product is used in the treatment of pathologies relating to human papilloma virus (HPV) infection; and TG4010 product is used in the treatment of non-small cell lung cancer. Prescient Therapeutics is headquartered in Melbourne, Victoria, Australia.

Prescient Therapeutics Ltd Key Recent Developments

May 26, 2015: Distinguished Moffitt Cancer Center Scientist Appointed Chief Scientific Officer
Apr 28, 2015: International Oncology Executive Appointed Prescient Chief Medical Officer

This comprehensive SWOT profile of Prescient Therapeutics Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Table Of Contents

Prescient Therapeutics Ltd (PTX) - Financial and Strategic SWOT Analysis Review
Table of Contents

Section 1 - About the Company

Prescient Therapeutics Ltd - Key Information
Prescient Therapeutics Ltd - Overview
Prescient Therapeutics Ltd - Key Employees
Prescient Therapeutics Ltd - Key Employee Biographies
Prescient Therapeutics Ltd - Key Operational Heads
Prescient Therapeutics Ltd - Major Products and Services
Prescient Therapeutics Ltd - History
Prescient Therapeutics Ltd - Company Statement
Prescient Therapeutics Ltd - Locations And Subsidiaries
Prescient Therapeutics Ltd - Key Manufacturing facilities
Head Office
Other Locations and Subsidiaries

Section 2 - Company Analysis

Prescient Therapeutics Ltd - Business Description
Prescient Therapeutics Ltd - Corporate Strategy
Prescient Therapeutics Ltd - SWOT Analysis
SWOT Analysis - Overview
Prescient Therapeutics Ltd - Strengths
Prescient Therapeutics Ltd - Weaknesses
Prescient Therapeutics Ltd - Opportunities
Prescient Therapeutics Ltd - Threats
Prescient Therapeutics Ltd - Key Competitors

Section 3 - Company Financial Performance Charts

Prescient Therapeutics Ltd - Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer


Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Prescient Therapeutics Ltd, Key Information
Prescient Therapeutics Ltd, Key Ratios
Prescient Therapeutics Ltd, Share Data
Prescient Therapeutics Ltd, Major Products and Services
Prescient Therapeutics Ltd, History
Prescient Therapeutics Ltd, Key Employees
Prescient Therapeutics Ltd, Key Employee Biographies
Prescient Therapeutics Ltd, Key Operational Heads
Prescient Therapeutics Ltd, Other Locations
Prescient Therapeutics Ltd, Subsidiaries
Prescient Therapeutics Ltd, Key Manufacturing facilities
Prescient Therapeutics Ltd, Key Competitors
Prescient Therapeutics Ltd, SWOT Analysis
Prescient Therapeutics Ltd, Ratios based on current share price
Prescient Therapeutics Ltd, Annual Ratios
Prescient Therapeutics Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Prescient Therapeutics Ltd, Performance Chart
Prescient Therapeutics Ltd, Ratio Charts

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.